The HrC Screening Test, short for Hormone Receptor Classification Screening Test is a diagnostic tool primarily used in oncology to evaluate hormone receptor status in certain types of cancers.
This test assesses the presence of hormone receptors (estrogen and progesterone receptors) in tumor tissues, helping healthcare providers determine the most effective treatment plans for patients.
1. Sample Collection
The test for HrC Screening typically begins with a tissue sample obtained from a biopsy or surgical procedure. This sample may be taken from the tumor itself or, in some cases, from surrounding lymph nodes. The procedure is performed by a qualified healthcare professional, ensuring that the sample collected is sufficient for analysis.
2. Laboratory Analysis
Once the tissue sample is collected, it is sent to a specialized laboratory for analysis. The laboratory employs immunohistochemistry (IHC) techniques to identify and quantify hormone receptors present in the tumor cells. The process involves staining the tissue sections with antibodies that bind specifically to estrogen and progesterone receptors.
A] Estrogen Receptor (ER) Testing: The presence of estrogen receptors is evaluated to determine if the cancer cells grow in response to estrogen. A positive result indicates that the cancer is likely to respond to hormone therapies that block estrogen.
B] Progesterone Receptor (PR) Testing: Similar to ER testing, the presence of progesterone receptors is assessed. Tumors that are positive for both estrogen and progesterone receptors are generally considered hormone receptor-positive cancers.
3. HrC Screening Test Results Pune
After the laboratory analysis, the HrC Screening test results are interpreted by a pathologist. The receptor status is typically reported as either positive or negative, along with a percentage indicating the proportion of cancer cells that express these receptors. For example, a report may indicate "ER-positive, 80%" meaning that 80% of the cancer cells have estrogen receptors.
A] Positive Results: These suggest that hormone therapies could be beneficial for the patient. The healthcare team may recommend treatments such as tamoxifen or aromatase inhibitors.
B] Negative Results: If the HrC Screening test pune shows that the cancer cells lack hormone receptors, the treatment approach may focus on chemotherapy, targeted therapies, or other options, as hormone therapies will likely be ineffective.
At Diagnopein, we offer comprehensive, accurate, and timely diagnostic services, including the HrC Screening Test. With our cutting-edge technology, and skilled technicians, you can be assured of reliable results every time. Get your results quickly, especially when time is crucial in detecting severe infections.
Competitive pricing without compromising on quality. Our team of experienced professionals ensures the test is conducted smoothly with minimal discomfort. We provide not just the HrC Screening test results but insights into your health condition, helping you and your doctor make informed decisions about treatment. For more information call us at +91 9204 108108.
The HrC Screening Test is generally safe, with minimal risks. The primary risk is related to the blood draw, such as slight bruising or discomfort.
Specific preparation may be required, such as fasting or avoiding certain medications. Your healthcare provider will give you detailed instructions based on your individual situation.
This test plays a crucial role in early detection, which can lead to more effective treatment options. Early diagnosis often improves outcomes and survival rates for various health conditions.
The HrC Screening Test typically involves a blood draw or a tissue sample, depending on the specific biomarkers being evaluated. The sample is then analyzed in a laboratory.
